technescan hdp -
curium netherlands b.v. - natriumoksidronat - preparasjonssett til radioaktive legemidler
tysabri
biogen netherlands b.v. - natalizumab - multippel sklerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
apresolin 25 mg
amdipharm ltd - hydralazinhydroklorid - tablett, drasjert - 25 mg
adenuric 80 mg
2care4 aps - febuksostat - tablett, filmdrasjert - 80 mg
adreview-iobenguane (123i) injection 74 mbq/ ml
ge healthcare b.v. - jobenguansulfat (123i) - injeksjonsvæske, oppløsning - 74 mbq/ ml
ceretec -
ge healthcare as - eksametazim - preparasjonssett til radioaktive legemidler
gallium (ga67) citrate 37 mbq/ ml
mallinckrodt medical b.v. - gallium (67ga) sitrat - injeksjonsvæske, oppløsning - 37 mbq/ ml
mibg [123i] 74 mbq/ ml
curium netherlands b.v. - jobenguansulfat (123i) - injeksjonsvæske, oppløsning - 74 mbq/ ml
metastron 150 mbq
ge healthcare b.v. - strontium (89sr) klorid - injeksjonsvæske, oppløsning - 150 mbq
myoview -
ge healthcare as - tetrofosmin - pulver til injeksjonsvæske, oppløsning